Cytek's 6% Q2 Rise Masked a 15% Expense Surge-Why That Matters Now

Slower Q2 revenue growth shifted the focus to spending discipline

Cytek's latest quarter sharpened an existing tension: demand is visible, but the business still needs to scale more decisively. The company reported Q2 revenue of $48.1 million, up 6% from a year earlier, while diluted GAAP EPS was -$0.09 versus -$0.04.

Bulls can point to real demand signals. Total recurring revenue reached $18.5 million in the second quarter, the installed base expanded to 3,933 Cytek instruments, and management cited strong double-digit revenue growth in instruments in the U.S. and in China. Bears, however, have the cleaner near-term argument: demand is there, but not yet fast enough to offset a faster rise in spend.

That mismatch is why this quarter matters. Operating expenses rose faster than revenue, turning a quarter that could have been read as steady execution into one that now asks for more proof.

The gross-margin headline improved, but the operating story weakened

The tariff refund improved margin optics

Reported GAAP gross margin rose to 59%, up from 52% a year earlier. But a one-time tariff refund accounted for most of the expansion. Excluding the refund, margin was 53%. That is an important distinction: one part of the quarter looked materially better on paper than the underlying operating picture.

Expense growth still outpaced revenue

The cleaner issue is operating discipline. Operating expenses reached $39.7 million, up 15%, while revenue grew 6%. That helped explain why losses widened despite better headline gross margin: loss from operations widened to $11.4 million from $10.6 million, and adjusted EBITDA turned from $1.3 million positive to $1.5 million negative.

Bulls can still argue the extra spend is productive. Cytek launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents and introduced Cytek Aurora™ Evo instrument configurations with expanded automation capabilities. Management also highlighted ongoing and consistent expansion of our service business. The bull case is that Cytek is investing in product differentiation and market reach at a time when the installed base is still growing.

Still, the near-term read remains cautious. The company is generating better product and service signals, but not yet fast enough financial leverage to fully justify the higher spend.

What would strengthen the story in coming quarters?

The next few quarters matter because they should show whether this quarter was build-out rather than sprawl. Cytek has enough operating leverage for the market to care, but after operating expenses rose 15% against 6% revenue growth, the burden is on future prints to improve the economics.

The key questions are straightforward:

• Is the installed base converting into stronger recurring revenue, not just a larger base?
• Does margin stay closer to the refund-adjusted level than to the headline number?
• Are Borealis and Aurora Evo helping adoption and service attachment in a measurable way?

With total recurring revenue reached $18.5 million in the second quarter and recurring revenue represented 35% of total revenue on a trailing-12-month basis, the setup is still investable. What it is not, yet, is a finished turnaround story.